Literature DB >> 2065854

Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients.

P Vardi1, L Crisa, R A Jackson.   

Abstract

We have followed-up 35 islet cell antibody-positive first degree relatives of patients with Type 1 (insulin-dependent) diabetes mellitus for an average of 1,300 days with sequential intravenous glucose tolerance tests. At the time of analysis and manuscript submission approximately half (18 of 35) had developed diabetes during follow-up. At initial intravenous glucose tolerance test, 11 had a 1 + 3 min insulin secretion below the first percentile of insulin secretion compared to 225 similarly studied normal control subjects. Six islet cell antibody positive relatives on follow-up developed an intravenous glucose tolerance test less than the first percentile. Fifteen out of 17 (88%) of these islet cell antibody positive relatives with secretion ever found to be below the first percentile are now overtly diabetic (positive predictive value = 88%) and insulin-treated, while only 3 of 18 (17%) without an intravenous glucose tolerance test demonstrating loss of first phase insulin secretion have progressed to diabetes (with approximately 1,300 days of follow-up for both groups relative risk or odds ratio with intravenous glucose tolerance test ever below vs never below the first percentile = 38, p less than 0.001). Intravenous glucose tolerance test response below the first percentile preceded diabetes by an average of 656 days. Even when first phase insulin secretion is below the first percentile, the absolute value of 1 + 3 min insulin above basal insulin correlates with the time to development of diabetes (r = 0.586, p less than 0.001). With our current duration of follow-up, the negative predictive value (intravenous glucose tolerance test never below the first percentile) is 83%, and overall accuracy 86%. Incidence rates of diabetes development amongst our islet cell antibody positive relatives with follow-up while intravenous glucose tolerance test is below the first percentile is 0.48 per year (15 conversions to diabetes amongst 17 relatives in 30.8 patient years of follow-up) vs 0.05 per year (three diabetic patients in 55.5 patient years) with intravenous glucose tolerance test greater than the first percentile.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2065854     DOI: 10.1007/BF00500379

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  12 in total

1.  Assay for islet cell antibodies. Protein A--monoclonal antibody method.

Authors:  S Srikanta; A Rabizadeh; M A Omar; G S Eisenbarth
Journal:  Diabetes       Date:  1985-03       Impact factor: 9.461

2.  Islet-cell antibodies are seldom transient.

Authors:  W Riley; N Maclaren
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

3.  The pattern of basal and stimulated insulin responses to intravenous glucose in first degree relatives of type 1 (insulin-dependent) diabetic children and unrelated adults aged 5 to 50 years.

Authors:  C P Smith; A J Williams; J M Thomas; H R Archibald; V D Algar; G F Bottazzo; E A Gale; M O Savage
Journal:  Diabetologia       Date:  1988-07       Impact factor: 10.122

4.  Diagnosis of pre-type I diabetes.

Authors:  H P Chase; M A Voss; N Butler-Simon; S Hoops; D O'Brien; M J Dobersen
Journal:  J Pediatr       Date:  1987-12       Impact factor: 4.406

5.  First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion.

Authors:  S Srikanta; O P Ganda; A Rabizadeh; J S Soeldner; G S Eisenbarth
Journal:  N Engl J Med       Date:  1985-08-22       Impact factor: 91.245

6.  Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus.

Authors:  H S Seltzer; E W Allen; A L Herron; M T Brennan
Journal:  J Clin Invest       Date:  1967-03       Impact factor: 14.808

7.  Pre-type I diabetes. Linear loss of beta cell response to intravenous glucose.

Authors:  S Srikanta; O P Ganda; R E Gleason; R A Jackson; J S Soeldner; G S Eisenbarth
Journal:  Diabetes       Date:  1984-08       Impact factor: 9.461

8.  Islet secretion in a new experimental model for non-insulin-dependent diabetes.

Authors:  G C Weir; E T Clore; C J Zmachinski; S Bonner-Weir
Journal:  Diabetes       Date:  1981-07       Impact factor: 9.461

9.  Progressive autoimmune beta cell insufficiency: occurrence in the absence of high-risk HLA alleles DR3, DR4.

Authors:  G S Eisenbarth; S Srikanta; E Fleischnick; O P Ganda; R A Jackson; S J Brink; J S Soeldner; E J Yunis; C Alper
Journal:  Diabetes Care       Date:  1985 Sep-Oct       Impact factor: 19.112

10.  Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction.

Authors:  S Srikanta; O P Ganda; R A Jackson; R E Gleason; A Kaldany; M R Garovoy; E L Milford; C B Carpenter; J S Soeldner; G S Eisenbarth
Journal:  Ann Intern Med       Date:  1983-09       Impact factor: 25.391

View more
  38 in total

Review 1.  Prediction and prevention of type I diabetes.

Authors:  R Gianani; G S Eisenbarth
Journal:  J Endocrinol Invest       Date:  1994 Jul-Aug       Impact factor: 4.256

2.  Normal values of first-phase insulin response to intravenous glucose in healthy Italian children and adolescents.

Authors:  R Lorini; M Vanelli
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

3.  Pressure-induced pain: early sign of diabetes-associated impairment of insulin production in rats.

Authors:  Dmitry Romanovsky; Maxim Dobretsov
Journal:  Neurosci Lett       Date:  2010-08-01       Impact factor: 3.046

Review 4.  Pharmacological approaches to the prevention of autoimmune diabetes.

Authors:  W E Winter; D V House; D Schatz
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 5.  Strategies for preventing type I diabetes mellitus.

Authors:  C F Verge; G S Eisenbarth
Journal:  West J Med       Date:  1996-03

6.  Quantification of human cytoplasmic islet-cell antibodies which cross-react with mouse pancreas: a follow-up study in type 1 (insulin-dependent) diabetic patients and in first-degree relatives.

Authors:  P Saï; A Elmansour; M Audrain; B Charbonnel; S Bardet
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

7.  Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset.

Authors:  Ele Ferrannini; Andrea Mari; Valentina Nofrate; Jay M Sosenko; Jay S Skyler
Journal:  Diabetes       Date:  2009-12-22       Impact factor: 9.461

8.  First phase insulin release and glucose tolerance in children with Fanconi anemia after hematopoietic cell transplantation.

Authors:  Lynda E Polgreen; William Thomas; Margaret L MacMillan; John E Wagner; Antoinette Moran; Anna Petryk
Journal:  Pediatr Blood Cancer       Date:  2009-08       Impact factor: 3.167

9.  Nicotinamide and insulin secretion in normal subjects.

Authors:  P J Bingley; G Caldas; R Bonfanti; E A Gale
Journal:  Diabetologia       Date:  1993-07       Impact factor: 10.122

10.  A novel hypomorphic PDX1 mutation responsible for permanent neonatal diabetes with subclinical exocrine deficiency.

Authors:  Marc Nicolino; Kathryn C Claiborn; Valérie Senée; Anne Boland; Doris A Stoffers; Cécile Julier
Journal:  Diabetes       Date:  2009-12-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.